-
1
-
-
0037097039
-
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
-
STOP-NIDDM Trail Research Group
-
Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359: 2072-7.
-
(2002)
Lancet
, vol.359
, pp. 2072-2077
-
-
Chiasson, J.L.1
Josse, R.G.2
Gomis, R.3
Hanefeld, M.4
Karasik, A.5
Laakso, M.6
-
2
-
-
60049089801
-
Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese type 2 diabetic patients
-
Narita T, Katsuura Y, Sato T. Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese type 2 diabetic patients. Diabet Med. 2009;26: 187-8.
-
(2009)
Diabet Med
, vol.26
, pp. 187-188
-
-
Narita, T.1
Katsuura, Y.2
Sato, T.3
-
3
-
-
0036708117
-
The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics
-
Lee A, Patrick P, Wishart J, Horowitz M, Morley JE. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab. 2002;4: 329-35.
-
(2002)
Diabetes Obes Metab
, vol.4
, pp. 329-335
-
-
Lee, A.1
Patrick, P.2
Wishart, J.3
Horowitz, M.4
Morley, J.E.5
-
4
-
-
33845539181
-
Pancreatic and extrapancreatic effects of gastric inhibitory polypeptide
-
Yamada Y, Miyawaki K, Tsukiyama K, Harada N, Yamada C, Seino Y. Pancreatic and extrapancreatic effects of gastric inhibitory polypeptide. Diabetes. 2006;55: 86-91.
-
(2006)
Diabetes
, vol.55
, pp. 86-91
-
-
Yamada, Y.1
Miyawaki, K.2
Tsukiyama, K.3
Harada, N.4
Yamada, C.5
Seino, Y.6
-
5
-
-
34447127048
-
Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets
-
Gault VA, McClean PL, Cassidy RS, Irwin N, Flatt PR. Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets. Diabetologia. 2007;50: 1752-62.
-
(2007)
Diabetologia
, vol.50
, pp. 1752-1762
-
-
Gault, V.A.1
McClean, P.L.2
Cassidy, R.S.3
Irwin, N.4
Flatt, P.R.5
-
6
-
-
0019865836
-
Rise in plasma concentration of aldosterone during long-term angiotensin II suppression
-
Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol. 1981;91(3): 457-65.
-
(1981)
J Endocrinol
, vol.91
, Issue.3
, pp. 457-465
-
-
Staessen, J.1
Lijnen, P.2
Fagard, R.3
Verschueren, L.J.4
Amery, A.5
-
7
-
-
0034006999
-
Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus
-
Scott LJ, Spencer CM. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. Drugs. 2000;59: 521-49.
-
(2000)
Drugs
, vol.59
, pp. 521-549
-
-
Scott, L.J.1
Spencer, C.M.2
-
8
-
-
79952173246
-
Comparing the efficacy of α-glucosidase inhibitors in suppressing postprandial hyperglycemia using continuous glucose monitoring: a pilot study-the MAJOR study
-
Tsujino D, Nishimura R, Taki K, Morimoto A, Tajima N, Utsunomiya K. Comparing the efficacy of α-glucosidase inhibitors in suppressing postprandial hyperglycemia using continuous glucose monitoring: a pilot study-the MAJOR study. Diabetes Technol Ther. 2011;13(3): 303-8.
-
(2011)
Diabetes Technol Ther
, vol.13
, Issue.3
, pp. 303-308
-
-
Tsujino, D.1
Nishimura, R.2
Taki, K.3
Morimoto, A.4
Tajima, N.5
Utsunomiya, K.6
-
9
-
-
83555168228
-
Effect of 3-month repeated administration of miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery disease
-
Emoto T, Sawada T, Yokoyama M. Effect of 3-month repeated administration of miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery disease. Am J Cardiol. 2012;109(1): 42-6.
-
(2012)
Am J Cardiol
, vol.109
, Issue.1
, pp. 42-46
-
-
Emoto, T.1
Sawada, T.2
Yokoyama, M.3
-
10
-
-
0030972122
-
The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone
-
Segal P, Feig PU, Schernthaner G. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone. Diabetes Care. 1997;20: 687-91.
-
(1997)
Diabetes Care
, vol.20
, pp. 687-691
-
-
Segal, P.1
Feig, P.U.2
Schernthaner, G.3
-
11
-
-
33745678261
-
The test meal A:A pilot model for the international standard of test meal for an assessment of both postprandial hyperglycemia and hyperlipidemia
-
Yoshino G. The test meal A: A pilot model for the international standard of test meal for an assessment of both postprandial hyperglycemia and hyperlipidemia. J Jpn Diabetes Soc. 2006;49: 361-71.
-
(2006)
J Jpn Diabetes Soc
, vol.49
, pp. 361-371
-
-
Yoshino, G.1
-
12
-
-
77955790218
-
Report of the Committee on the classification and diagnostic criteria of diabetes mellitus
-
The Committee of Japan Diabetes Society on the diagnostic criteria of diabetes mellitus
-
The Committee of Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Jpn Diabetes Soc. 2010;53: 450-67.
-
(2010)
J Jpn Diabetes Soc
, vol.53
, pp. 450-467
-
-
-
13
-
-
0012184784
-
Insulin as a cause of extreme hyperglycemia and instability
-
Somogyi M. Insulin as a cause of extreme hyperglycemia and instability. Week Bull St Louis Med Soc. 1938;32: 498-510.
-
(1938)
Week Bull St Louis Med Soc
, vol.32
, pp. 498-510
-
-
Somogyi, M.1
-
14
-
-
48849115247
-
Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects
-
Arakawa M. Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects. Metabolism. 2008;57: 1299-306.
-
(2008)
Metabolism
, vol.57
, pp. 1299-1306
-
-
Arakawa, M.1
-
15
-
-
17144398850
-
α-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in type 2 diabetic patients
-
Hücking K, Kostic Z, Pox C. α-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in type 2 diabetic patients. Diabet Med. 2005;22: 470-6.
-
(2005)
Diabet Med
, vol.22
, pp. 470-476
-
-
Hücking, K.1
Kostic, Z.2
Pox, C.3
-
17
-
-
77952267060
-
Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study
-
Kato T, Inoue T, Node K. Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study. Cardiovasc Diabetol. 2010;9: 12.
-
(2010)
Cardiovasc Diabetol
, vol.9
, pp. 12
-
-
Kato, T.1
Inoue, T.2
Node, K.3
-
18
-
-
0031820109
-
Asymptomatic hyperglycaemia and early atherosclerotic changes
-
Kawamori R. Asymptomatic hyperglycaemia and early atherosclerotic changes. Diabetes Res Clin Pract. 1998;40: S35-42.
-
(1998)
Diabetes Res Clin Pract
, vol.40
-
-
Kawamori, R.1
-
19
-
-
77954501338
-
Single administration of α-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease
-
Hiki M, Shimada K. Single administration of α-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease. Circ J. 2010;74: 1471-8.
-
(2010)
Circ J
, vol.74
, pp. 1471-1478
-
-
Hiki, M.1
Shimada, K.2
-
20
-
-
0029886788
-
Improvement of insulin sensitivity and dyslipidemia with a new alpha-glucosidase inhibitor, voglibose, in nondiabetic hyperinsulinemic subjects
-
Shinozaki K, Suzuki M, Ikebuchi M, Hirose J, Hara Y, Harano Y. Improvement of insulin sensitivity and dyslipidemia with a new alpha-glucosidase inhibitor, voglibose, in nondiabetic hyperinsulinemic subjects. Metabolism. 1996;45: 731-7.
-
(1996)
Metabolism
, vol.45
, pp. 731-737
-
-
Shinozaki, K.1
Suzuki, M.2
Ikebuchi, M.3
Hirose, J.4
Hara, Y.5
Harano, Y.6
-
21
-
-
0002633391
-
Decreased GIP secretion through impairment of absorption
-
Ebert R, Creutzfeldt W. Decreased GIP secretion through impairment of absorption. Front Horm Res. 1980;7: 192-210.
-
(1980)
Front Horm Res
, vol.7
, pp. 192-210
-
-
Ebert, R.1
Creutzfeldt, W.2
-
22
-
-
0035954846
-
Postprandial dyslipidemia: an atherogenic disorder common in patients with diabetes mellitus
-
Ginsberg HN, Illingworth DR. Postprandial dyslipidemia: an atherogenic disorder common in patients with diabetes mellitus. Am J Cardiol. 2001;88: 09-15.
-
(2001)
Am J Cardiol
, vol.88
, pp. 09-15
-
-
Ginsberg, H.N.1
Illingworth, D.R.2
-
23
-
-
4444293785
-
Acarbose lowers serum triglyceride and postprandial chylomicron levels in type 2 diabetes
-
Ogawa S, Takeuchi K, Ito S. Acarbose lowers serum triglyceride and postprandial chylomicron levels in type 2 diabetes. Diabetes Obes Metab. 2004;6: 384-90.
-
(2004)
Diabetes Obes Metab
, vol.6
, pp. 384-390
-
-
Ogawa, S.1
Takeuchi, K.2
Ito, S.3
-
24
-
-
84857034273
-
Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients
-
Narita T, Yokoyama H, Yamashita R, Sato T, Hosoba M, Morii T, Fujita H, Tsukiyama K, Yamada Y. Comparisons of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients. Diabetes Obes Metab. 2012;14(3): 283-7.
-
(2012)
Diabetes Obes Metab
, vol.14
, Issue.3
, pp. 283-287
-
-
Narita, T.1
Yokoyama, H.2
Yamashita, R.3
Sato, T.4
Hosoba, M.5
Morii, T.6
Fujita, H.7
Tsukiyama, K.8
Yamada, Y.9
|